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OBJECTIVES We sought to examine the effect of intravenous beta-blockers administered before primary
percutaneous coronary intervention (PCI) on survival and myocardial recovery after acute
myocardial infarction (AMI).
BACKGROUND Studies of primary PCI but not thrombolysis have suggested that beta-blocker administration
before reperfusion may enhance survival. Whether oral beta-blocker use before admission
modulates this effect is unknown.
METHODS The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complica-
tions (CADILLAC) trial randomized 2,082 AMI patients to either stenting or balloon
angioplasty, each  abciximab. In accordance with the protocol, intravenous beta-blockers
were administered before PCI in the absence of contraindications.
RESULTS A total of 1,136 patients (54.5%, BB group) received beta-blockers before PCI, whereas
946 (45.5%, BB group) did not. The 30-day mortality was significantly lower in the BB
group than in the BB group (1.5% vs. 2.8%, p  0.03), an effect entirely limited to patients
who had not been receiving beta-blockers before admission (1.2% vs. 2.9%, p  0.007). In
contrast, no survival benefit with pre-procedural beta-blockers was observed in patients
receiving beta-blockers at home (3.3% vs. 1.9%, respectively, p  0.47). By multivariate
analysis, pre-procedural beta-blocker use was an independent predictor of lower 30-day
mortality among patients without previous beta-blocker therapy (relative risk  0.38 [95%
confidence interval 0.17 to 0.87], p  0.02). The improvement in left ventricular ejection
fraction from baseline to seven months was also greater after intravenous beta-blockers (3.8%
vs. 1.3%, p  0.01), an effect limited to patients not receiving oral beta-blockers before
admission.
CONCLUSIONS In patients with AMI undergoing primary PCI, myocardial recovery is enhanced and 30-day
mortality is reduced with pre-procedural intravenous beta-blockade, effects confined to
patients untreated with oral beta-blocker medication before admission. (J Am Coll Cardiol
2004;43:1780–7) © 2004 by the American College of Cardiology Foundationr
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oespite advances in reperfusion therapy for acute myocar-
ial infarction (AMI), a significant proportion of patients
till develop recurrent ischemia, reinfarction, and malignant
See page 1788
entricular arrhythmias, and/or they die. Whether prophy-
actic intravenous beta-adrenergic blocker therapy before
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Manuscript received August 13, 2003; revised manuscript received October 13,P003, accepted October 20, 2003.eperfusion improves survival is undetermined. Historically,
everal studies demonstrated reduced mortality in patients
reated with intravenous beta-blockers in AMI without
eperfusion therapy (1–3). Conversely, trials of intravenous
eta-blockers in patients treated with thrombolytic therapy,
hile demonstrating reductions in recurrent ischemia, have
eported either no survival benefit (4,5) or increased mor-
ality (6). A recent report from the Primary Angioplasty in
yocardial Infarction (PAMI) trials found intravenous
eta-blocker administration before percutaneous coronary
ntervention (PCI) to be associated with improved in-
ospital survival and reductions in procedural complica-
ions, including serious arrhythmias and the need for intra-
ortic balloon counterpulsation (7).
To confirm and further explore the early and late benefits
f intravenous beta-blocker administration before primary
CI, we examined the database from a large, prospective,
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MI, the Controlled Abciximab and Device Investigation
o Lower Late Angioplasty Complications (CADILLAC)
rial. Moreover, we hypothesized that the utility of these
gents would be most evident in or confined to those
atients not maintained on oral beta-blocker therapy before
dmission.
ETHODS
etails of the CADILLAC trial have been previously
eported (8). Briefly, 2,082 patients 18 years of age with
MI and symptom onset within 12 h undergoing primary
CI were randomized to primary balloon angioplasty versus
ultilink stent implantation, each  abciximab. The prin-
ipal clinical exclusion criterion was cardiogenic shock.
ngiographic inclusion criteria required eligibility for stent
mplantation, including a native coronary artery culprit
essel with reference diameter 2.5 to 4.0 mm and lesion
ength 64 mm. By protocol, intravenous beta-blockers
e.g., metoprolol 5 mg intravenously over 2 min, given every
min up to 3 doses) were strongly recommended before
atheterization or intervention, in the absence of clinical
ontraindications. Detailed information on medication us-
ge was collected at the time of admission, in the emergency
oom, in the catheterization suite, during the hospitaliza-
ion, at discharge, and during the clinical follow-up periods
f 1, 6, and 12 months. For the purpose of the current
nalysis, pre-procedural beta-blocker use was defined as any
n-hospital administration of a beta-blocker before arrival in
he catheterization laboratory or before balloon inflation.
nd points and statistical analysis. The primary end
oint was a composite of major adverse cardiac events,
efined as death from any cause, reinfarction, repeat target
essel revascularization as a result of ischemia, or disabling
troke. The components of the composite end point have
een previously defined (8). Severe hypotension before PCI
as defined as systolic blood pressure 90 mm Hg for 30
in or requiring pressor therapy. Severe bradyarrhythmia
efore PCI was defined as asystole or bradycardia requiring
tropine or pacing. Quantitative coronary angiography and
entriculographic assessment were performed using dedi-
Abbreviations and Acronyms
AMI  acute myocardial infarction
CADILLAC  Controlled Abciximab and Device
Investigation to Lower Late Angioplasty
Complications
CI  confidence interval
HR  hazard ratio
LVEF  left ventricular ejection fraction
PAMI  Primary Angioplasty in Myocardial
Infarction
PCI  percutaneous coronary intervention
TIMI  Thrombolysis In Myocardial Infarctionated software (QCA-CMS, MEDIS, Leiden, the Nether-ands) at an independent core angiographic laboratory at the
ardiovascular Research Foundation in New York (8).
ntegrade coronary blood flow was evaluated using the
hrombolysis In Myocardial Infarction (TIMI) scale (9).
eft ventricular ejection fraction (LVEF) was calculated
sing the length-area method (10), and regional wall mo-
ion was calculated using the centerline chord method (11).
Categorical data were compared using the Fisher exact
est. Continuous variables are presented as medians and
nterquartile ranges and were compared using the Kruskal-
allis non-parametric test. Clinical outcomes are presented
s Kaplan-Meier survival estimates and were compared
sing the log-rank test. Independent predictors of survival
ere determined with Cox proportional hazard regression
nalysis using stepwise selection of correlative univariate
linical and angiographic parameters with entry and exit
riteria of p  0.1. Independent predictors of improvement
n LVEF from baseline to follow-up were determined by
ultiple linear regression using stepwise selection with
ntry and exit criteria of p  0.1. All baseline variables in
able 1 were available for selection in these models, along
ith stent and abciximab randomization and pre-procedural
ntravenous beta-blocker use. For all analyses, a two-sided p
0.05 was considered statistically significant.
ESULTS
aseline characteristics. Pre-procedural beta-blockers
ere administered in 1,136 (54.5%) patients (BB group)
nd were not given to the remaining 946 patients (45.5%,
B group). As seen in Table 1, pre-procedural beta-
locker therapy was more frequently administered at U.S.
ites than non U.S. sites. The BB patients were younger
nd less frequently had pre-existing renal failure, previous
MI, or previous PCI but were more likely to have
ypertension and anterior infarction with depressed global
nd regional left ventricular function. TIMI flow grade 3 at
aseline angiography was present in slightly more patients
ho received pre-procedural beta-blockers than in those
ho did not, and symptom onset to first balloon inflation
as slightly longer with pre-procedural beta-blocker use.
re-procedural beta-blocker therapy and clinical out-
omes. Clinical outcomes during PCI and throughout the
ndex hospitalization are shown in Table 2. New onset
ongestive heart failure in the catheterization laboratory was
lightly more frequent in patients treated with pre-
rocedural beta-blockers. Stent and abciximab use and final
rocedural success rates, including TIMI flow grade 3
chieved and luminal dimensions, were similar in the BB
nd BB groups. In-hospital mortality was significantly
ower and the length of hospitalization shorter among BB
han among BB patients (Table 2). Patients receiving
re-procedural beta-blockers were more likely to be dis-
harged receiving statins, angiotensin-converting inhibitors,
nd oral beta-blockers.At 30 days, mortality was significantly reduced in BB
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isk reduction in 30-day mortality with pre-procedural
eta-blocker therapy was 1.7%, corresponding to a hazard
atio (HR) of 0.52 (95% confidence interval [CI] 0.28 to
.95). There were no differences, however, in the 30-day
ates of reinfarction (0.8% vs. 0.9%, p  0.88), target vessel
evascularization (3.4% vs. 3.5%, p  0.84), or disabling
troke (0.2% vs. 0.1%, p  0.68) in the BB and BB
roups, respectively.
At one year, the absolute risk reduction in mortality in
he BB compared with the BB group was 1.2% (Fig. 1),
hough with increasing mortality in both groups this was no
onger significant (HR  0.74 [95% CI 0.49 to 1.12], p 
.15).
mpact of pre-hospital oral beta-blocker therapy. The
ffect of pre-procedural intravenous beta-blocker adminis-
ration on 30-day survival was strongly influenced by routine
ral beta-blocker use before admission, as depicted in Figure
. Pre-procedural beta-blocker administration markedly
educed 30-day mortality in patients not maintained on this
lass of agents at home (from 2.9% to 1.2%, HR  0.40
95% CI 0.20 to 0.80], p  0.007), whereas patients taking
ral beta-blocker therapy did not benefit by pre-procedural
ntravenous beta-blocker administration (30-day mortality
Table 1. Baseline Characteristics of Patients S
Clinical features
U.S. site (%)
Age (yrs)
Male gender (%)
Diabetes mellitus (%)
Current smoker (%)
Hypercholesterolemia (%)
Hypertension (%)
Previous myocardial infarction (%)
Previous coronary angioplasty (%)
Renal insufficiency (CrCl 60 ml/min)
Chest pain to first balloon inflation (hr)
Killip class 2 or 3 (%)
Pre-admission medications
Aspirin (%)
Beta-blockers (%)
Statins (%)
Calcium blockers (%)
ACE inhibitors/ARB (%)
Thienopyridines (%)
Angiographic features
Three-vessel disease (%)
Infarct vessel  left anterior descending (%)
Reference vessel diameter (mm)
Diameter stenosis (%)
TIMI flow grade 3 (%)
Left ventricular ejection fraction (%)
Infarct zone regional wall motion
(SD/chord)

Continuous variables are expressed as median, with interqua
ACE  angiotensin-converting enzyme; ARB  angio
clearance; SD  standard deviation; TIMI  Thrombolysis.3% vs. 1.9% in the BB group, HR  1.68 [95% CI 0.40 Bo 7.00], p  0.47). By multivariate analysis, pre-procedural
eta-blocker administration was an independent predictor
f 30-day survival in patients not taking beta-blockers
efore admission (Table 3).
Paired left ventriculograms were available at baseline and
t protocol-specified seven-month angiographic follow-up
or 230 and 233 patients in the BB and BB groups,
espectively. Baseline LVEF was lower in BB patients,
hough seven-month follow-up LVEF was similar in both
roups, corresponding to a significantly greater incremental
mprovement in LVEF in the BB group compared with
he BB group (Fig. 3). The increase in LVEF from
aseline to follow-up in the BB group was most pro-
ounced in patients not taking oral beta-blockers before
dmission. In patients maintained on beta-blockers before
dmission, the change in LVEF was similar in BB and
B patients. By multiple linear regression, pre-procedural
ntravenous beta-blocker administration in patients not
eceiving oral beta-blockers before admission was an inde-
endent predictor of greater increase in LVEF from base-
ine to seven-month follow-up (beta coefficient  3.24, p 
.0001).
nalyses excluding patients with hemodynamic and elec-
rical instability before catheterization. Compared with
ed by Pre-Procedural Beta-Blocker Therapy
 Group
 1,136)
BB Group
(n  946) p Value
90.9 70.8 0.0001
(49.0, 67.0) 62.0 (52.0, 70.0) 0.0001
72.9 73.2 0.92
17.3 15.9 0.40
43.9 42.2 0.42
38.0 37.7 0.93
50.2 45.6 0.04
11.8 16.0 0.006
9.5 13.2 0.008
15.4 21.3 0.0009
3.0, 6.5) 3.8 (2.7, 5.7) 0.0001
10.5 11.3 0.62
26.6 27.9 0.52
13.5 16.4 0.06
12.5 11.2 0.38
15.0 16.2 0.47
10.2 8.5 0.18
1.9 3.4 0.052
15.4 15.8 0.86
42.3 30.0 0.0001
2.6, 3.3) 2.95 (2.6, 3.3) 0.35
74.1, 100) 100 (76.3, 100) 0.052
23.8 20.0 0.04
46.1, 62.1) 57.7 (48.9, 64.3) 0.0001
1.68, 0.89) 1.24 (1.61, 0.82) 0.007
nge in parentheses.
receptor blockers; BB  beta-blocker; CrCl  creatinine
yocardial Infarction.tratifi
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2.95 (
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2.4% vs. 0.7%, p  0.001, and 7.1% vs. 2.7%, p  0.0001,
espectively). Therefore, analyses were also performed after
he exclusion of the 118 patients with these confounding
onditions. In this cohort (n  1,964), a trend towards
educed 30-day mortality was observed in BB compared
ith BB patients (1.4% vs. 2.3%, HR  0.56 [95% CI
.29 to 1.08], p  0.08). Among patients without pread-
ission oral beta-blocker therapy, 30-day mortality was
Table 2. Catheterization Laboratory and In-H
Interventional strategy
Stent implanted (%)
Abciximab administered (%)
Catheterization laboratory complications
Heart failure not present on admission (%)
Use of intra-aortic balloon pump (%)
Serious arrhythmia* (%)
Cardioversion (%)
Defibrillation (%)
Cardiopulmonary resuscitation (%)
Intubation (%)
Final results
TIMI flow grade 3 (%)
Reference vessel diameter (mm)
In-lesion minimal luminal diameter (mm)
In-lesion diameter stenosis (%)
In-hospital results
Mortality (%)
Length of stay (days)
Discharge medications
Aspirin (%)
Beta-blockers (%)
Statins (%)
Calcium blockers (%)
ACE inhibitors/ARB (%)
Thienopyridines (%)
*Arrhythmia requiring medication, electrical intervention, or
Abbreviations as in Table 1.
igure 1. Freedom from death among patients treated (BB, solid line) o
efore percutaneous coronary intervention. BB  beta-blocker.ignificantly lower in BB compared with BB patients
1.1% vs. 2.5%, HR  0.40 [95% CI 0.19 to 0.86], p 
.001). Among patients receiving oral beta-blocker therapy
efore admission, however, 30-day mortality was not sig-
ificantly different in BB versus BB patients (3.4% vs.
.5%, respectively, HR 2.27 [95% CI 0.44 to 11.72], p
.31). By multivariate analysis, intravenous beta-blocker
herapy remained an independent correlate of improved
urvival in patients previously untreated with beta-blockers
al Outcomes
 Group
 1,136)
BB Group
(n  946) p Value
56.1 57.6 0.50
52.2 54.2 0.38
1.1 0.3 0.05
0.1 0.5 0.10
5.4 5.9 0.63
0.5 0.1 0.13
1.1 0.7 0.49
0.0 0.1 0.99
0.4 0.5 0.73
96.1 95.0 0.28
(2.63, 3.34) 2.99 (2.64, 3.38) 0.20
(1.94, 2.59) 2.25 (1.95, 2.60) 0.49
(9.2, 27.0) 17.9 (8.7, 27.3) 0.79
1.1 2.2 0.057
(2.8, 4.7) 3.9 (2.8, 6.0) 0.001
96.8 96.6 0.91
85.8 70.8 0.0001
32.8 25.7 0.0005
4.6 5.6 0.31
36.8 32.4 0.04
67.1 67.9 0.74
pulmonary resuscitation.
treated (BB, broken line) with pre-procedural intravenous beta-blockersospit
BB
(n
2.97
2.25
18.1
3.3
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hose receiving previous oral beta-blocker therapy (HR 
.76 [95% CI 0.27 to 2.13], p  0.60).
Similarly, among patients untreated with oral beta-
lockers before admission, the recovery in LVEF was
reater in BB patients than in BB patients (5.4% [95%
I 2.8 to 13.3] vs. 2.3% [95% CI 5.4 to 7.8], p  0.01). In
atients taking beta-blockers before admission, the change
n LVEF was similar in BB and BB patients (1.2%
95% CI 4.6 to 6.5] vs. 0.5% [95% CI 7.4 to 2.0], p
0.77). By linear regression, pre-procedural intravenous
eta-blocker administration remained an independent pre-
ictor of a greater increase in LVEF from baseline to
ollow-up in patients not receiving oral beta-blockers before
dmission (beta coefficient  3.20, p  0.01).
ISCUSSION
he main findings of the present study are as follows: 1)
re-procedural administration of intravenous beta-blockers
n patients with AMI treated by contemporary primary PCI
trategies resulted in reduced mortality and enhanced recov-
able 3. Multivariate Predictors of 30-Day Mortality Stratified
y Pre-Admission Beta-Blocker Use
Hazard Ratio
(95% CI) p Value
o pre-admission beta-blocker use
Hypercholesterolemia 0.24 (0.07, 0.80) 0.02
Pre-procedural beta-blocker therapy 0.38 (0.17, 0.87) 0.02
Killip class 2 or 3 2.77 (1.21, 6.34) 0.02
Hypertension 3.70 (1.53, 8.97) 0.004
Renal failure (CrCl 60 ml/min) 4.41 (1.97, 9.86) 0.0003
Infarct vessel  left anterior
descending
4.64 (1.92, 11.19) 0.0006
re-admission beta-blocker use*
Pre-procedural beta-blocker therapy 1.68 (0.40, 7.02) 0.47
No significant variables were identified.
igure 2. Hazard ratios for 30-day mortality in CADILLAC patients with
tratified by pre-percutaneous coronary intervention intravenous beta-bloceCI  confidence interval; CrCl  creatinine clearance.ry of left ventricular function; and 2) these benefits were
onfined to patients who were not maintained on oral
eta-blocker therapy before admission.
mpact of beta-blocker use before admission. The results
f the present study confirm the survival advantage con-
erred by pre-procedural intravenous beta-blocker adminis-
ration in patients with AMI undergoing primary PCI
reviously reported by the PAMI investigators (7). The
urrent analysis importantly extends these findings, how-
ver, by identifying a strong interaction between pre-
dmission oral beta-blocker therapy and the efficacy of
re-procedural intravenous beta-blockers in terms of reduc-
ng mortality and enhancing myocardial recovery. We hy-
othesized that patients unprotected at the time of AMI
nset by long-term oral beta-blocker therapy would derive
he greatest clinical benefit from intravenous administration
f these agents before PCI. Indeed, in this group of patients,
ut not in patients who had been receiving oral beta-
lockers before hospitalization, pre-procedural intravenous
eta-blockade resulted in a significant reduction in 30-day
ortality. The absolute mortality reduction in this group at
0 days was 1.7%, corresponding to 59 patients needing to
e treated in order to save one life. This absolute increase in
urvival was largely maintained over one year (1.2%), though
ith incremental mortality over time in both groups the
ssociation was no longer of statistical significance.
Baseline LVEF determined by left ventriculography at
he time of PCI was lower in BB compared with BB
atients, possibly owing to selection bias (treatment of
icker patients with intravenous beta-blockers). The degree
f LVEF recovery from baseline to follow-up was greater in
he BB group, however, such that follow-up LVEF was
omparable in both groups. As previous studies during
volving AMI have shown that LVEF is not depressed
mmediately after intravenous beta-blockers (12,13), the
ect to oral beta-blocker medication use before acute myocardial infarction,
ministration.respnhancement of myocardial recovery by the administration
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May 19, 2004:1780–7 Intravenous Beta-Blockade in AMI Managed By Primary PCIf intravenous beta-blockers is unlikely be explained by
rtificial suppression of systolic function. Similar to the
ffect on survival, the incremental recovery in LVEF with
re-procedural beta-blockers compared with no such ther-
py was confined to patients previously untreated with oral
eta-blockers. In this group, pre-procedural intravenous
eta-blocker use was an independent predictor of global
yocardial recovery from baseline to seven months. To our
nowledge, the enhanced recovery in LVEF with pre-
eperfusion intravenous beta-blocker use has not previously
een described.
revious studies of early beta-blockade in AMI. Previous
nalyses of the effect of beta-blocker administration during
he early phases of AMI on survival have resulted in varying
onclusions, depending on the use and type of reperfusion
herapy. In the First International Study of Infarct Survival
ISIS-1) trial, conducted in the era preceding reperfusion
herapy, intravenous atenolol followed by one week of oral
herapy reduced in-hospital mortality by 15% in more than
6,000 enrolled patients (1). A meta-analysis confirmed the
enefit of intravenous beta-blockers in reducing early mor-
ality in the pre-thrombolytic era (14). However, random-
zed trials of intravenous beta-blocker administration in
atients treated with thrombolytic therapy failed to demon-
trate a salutary effect on survival (3–5). Indeed, a retrospec-
ive analysis of the Global Utilization of Streptokinase and
igure 3. Change in left ventricular ejection fraction (LVEF) from baselin
solid bars) and BB (open bars) denote patients treated or untreated wit
ars  follow-up LVEF.PA (alteplase) for Occluded Coronary Arteries (GUSTO-I)rial actually suggested that intravenous atenolol might
ncrease mortality (6). Conversely, in the PAMI trials,
eta-blocker use preceding primary PCI was associated with
mproved in-hospital survival (7). Similarly, in the present
tudy, pre-procedural administration of intravenous beta-
lockers was associated with reduced mortality at 30 days, a
eduction that first became significant during the index
ospitalization. By multivariate analysis, pre-procedural in-
ravenous beta-blocker use in patients not previously main-
ained on oral beta-blockers was an independent predictor
f survival, suggesting a possible causative relationship.
The mechanisms through which pre-procedural intrave-
ous beta-blockers may reduce mortality in patients with
MI not maintained on oral beta-blocker therapy under-
oing primary PCI are unknown. Unlike the findings
eported by the PAMI trialists (7), potentially lethal proce-
ural complications such as arrhythmias or the need for
ntra-aortic balloon counterpulsation were not reduced by
re-procedural beta-blockade in the present study. A pos-
ible alternative mechanism might be a reduction in infarct
ize with beta-blocker administration (15,16). Some studies
17,18), but not all (19), have found that oral or intracoro-
ary beta-blocker use before elective PCI attenuates
rocedure-related myonecrosis. The greater extent of myo-
ardial recovery occurring in patients pre-treated with in-
ravenous beta-blockers in the present study supports this
ossibility. Less obvious is why such an effect would be
even-month follow-up among patients with paired ventriculograms. BB
-procedural beta-blockers, respectively. Solid bars  index LVEF. Opene to s
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Intravenous Beta-Blockade in AMI Managed By Primary PCI May 19, 2004:1780–7onfined to patients not recently exposed to beta-blockers,
hough alterations in myocardial expression of beta-
drenoreceptors might be a possible explanation (20–22).
he propensity for patients receiving pre-procedural intra-
enous beta-blockers to be discharged while receiving st-
tins, angiotensin-converting enzyme inhibitors, and oral
lockers might also contribute to enhanced late outcomes,
hough most of the benefit of intravenous beta-blockade in
educing mortality was seen before discharge, and by mul-
ivariate analysis in this study, discharge use of these agents
as not an independent determinant of late survival.
tudy limitations. The decision to use intravenous beta-
lockers was not randomized, and the present analyses
including the pre-admission oral beta-blocker stratifica-
ion) were post hoc. These findings must therefore be
onsidered hypothesis-generating rather than definitive.
owever, pending the performance of a randomized trial
nvestigating the role of pre-procedural intravenous beta-
lockade in primary PCI, these data from a large patient
opulation collected in a carefully controlled study provide
elevant clinical evidence. Moreover, the benefit of pre-
rocedural beta-blockers in reducing mortality and enhanc-
ng myocardial recovery in patients not admitted while
eceiving oral beta-blocker therapy persisted when patients
n whom beta-blocker therapy was contraindicated, includ-
ng those with profound hypotension and severe brady-
rrhythmias, were excluded from the analysis. The fact that
o independent correlates of survival were identified in
atients admitted while receiving oral beta-blockers is most
ikely due to the relatively small size of this group (n 308).
he applicability of our findings to patient populations
nder-represented in CADILLAC (e.g., octogenarians) is
nknown. Lastly, the specific beta-blockers and precise
oses used were not analyzed, and thus recommendations
egarding the optimal pre-procedural beta-blockade regi-
en cannot be made.
linical implications. The present study supports the
outine administration of intravenous beta-blocker therapy
n patients with AMI not maintained on oral beta-blockers
efore primary PCI, in the absence of absolute contraindi-
ations, and emphasizes that such therapy may improve
urvival and enhance myocardial recovery in these patients.
hese results should not, however, be construed to suggest
hat patients maintained on oral beta-blocker medication be
enied intravenous beta-blockers before primary PCI, espe-
ially in those with a “hyperdynamic” state, including
ypertension and/or tachycardia (23). Notably, nearly half
he patients in CADILLAC were not prescribed intrave-
ous beta-blockers despite protocol recommendations. Al-
hough detailed explanations as to why beta-blockers were
ithheld were not collected, it is unlikely that strict contra-
ndications were present in most patients. It is well known
hat beta-blockers are frequently under-prescribed in the
eri-infarct period (24,25), possibly reflecting physicians’
oncerns about their safety in the AMI setting and miscon-
eptions regarding absolute versus relative contraindications26). In the present study, intravenous beta-blocker admin-
stration was safe, being associated only with a slight
ncrease in the incidence of transient peri-procedural heart
ailure, without increases in adverse events such as brady-
rrhythmias or severe hypotension. This safety profile,
oupled with the potential benefits of enhanced survival and
yocardial recovery, reinforce the importance of the admin-
stration of pre-procedural intravenous beta-blockers to
ost patients with AMI before primary PCI, especially
hose not maintained on oral beta-blocker therapy at the
ime of admission.
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